Sanofi SA has disclosed that it is making a $9.3 billion, non-binding bid for Medivation Inc of California, US which has at least two cancer products in mid-to-late stage development and a product for prostate cancer that it is marketing jointly with Astellas Pharma Inc of Japan.
